Literature DB >> 8784092

Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy.

S Muttukrishna1, P A Fowler, L George, N P Groome, P G Knight.   

Abstract

The main objective of this study was to determine whether activin A concentrations in peripheral blood fluctuate during the normal human menstrual cycle and pregnancy. Blood samples were collected longitudinally from five regularly cycling volunteers (22-30 yr) throughout a spontaneous menstrual cycle and cross-sectionally from normal pregnant women attending the antenatal clinic (8-38 weeks gestation: 3-20 subjects/time point). Total (i.e. bound plus free) activin A concentrations were measured using a recently developed two-site enzyme immunoassay that employs an analyte denaturation/oxidation step to eliminate interference due to endogenous activin-binding proteins. During the menstrual cycle, mean serum activin A levels varied in a biphasic manner (by ANOVA, P = 0.02), with highest levels around midcycle (approximately 220 pg/mL) and the late luteal/early follicular phase (approximately 310 pg/mL) and nadirs in both midfollicular (approximately 125 pg/mL) and midluteal (approximately 120 pg/mL) phases. Between the mid- to late luteal phase, the activin A level increased progressively (approximately 2.5-fold; P < 0.05), whereas inhibin A, estradiol, and progesterone all decreased progressively (approximately 10-fold; P < 0.001). During pregnancy, serum activin A levels were much higher than those in nonpregnant subjects, with a value of 2.12 +/- 0.31 ng/mL recorded in week 8. Levels remained at approximately 2 ng/mL between weeks 8-24, but increased thereafter to reach 25.5 +/- 6 ng/mL by week 38, a value approximately 100 times greater than that during the normal menstrual cycle. Serum activin A levels during pregnancy were significantly correlated with inhibin A (r = 0.69; P < 0.001), estradiol (r = 0.55; P < 0.001), and progesterone (r = 0.74; P < 0.001) values. Gel permeation chromatography indicated that all of the detectable activin A in human follicular fluid, pregnancy serum, and term placental extract eluted with an apparent molecular mass between 70-200 kDa, indicating that little, if any, free activin (molecular mass, 25 kDa) is present in these samples. Although these results support a possible endocrine role for circulating activin A during the human menstrual cycle and pregnancy, the observation that all detectable activin A is associated with binding protein(s) raises questions about its relative bioavailability for action on peripheral target cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784092     DOI: 10.1210/jcem.81.9.8784092

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition.

Authors:  Nancy E Reame; Jane L Lukacs; Pamela Olton; Rudi Ansbacher; Vasantha Padmanabhan
Journal:  Fertil Steril       Date:  2007-04-16       Impact factor: 7.329

Review 2.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

3.  Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy.

Authors:  P Florio; S Luisi; E Casarosa; A R Genazzani; P Pautier; C Lhommé; J M Bidart; P G Driul; F Petraglia
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

4.  Engineering the ovarian cycle using in vitro follicle culture.

Authors:  Robin M Skory; Yuanming Xu; Lonnie D Shea; Teresa K Woodruff
Journal:  Hum Reprod       Date:  2015-03-16       Impact factor: 6.918

5.  Activin A is stimulated by tumor necrosis factor-alpha and modulates collagen gene expression in human amniotic cells.

Authors:  Y Abe; M Komatsubara; M Saito; M Toda; H Shinozaki; T Tamura; Y Kasahara; H Sedakata; T Minegishi
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

6.  Regulation of the activins-follistatins-inhibins axis by energy status: Impact on reproductive function.

Authors:  Nikolaos Perakakis; Jagriti Upadhyay; Wael Ghaly; Joyce Chen; Pavlina Chrysafi; Athanasios D Anastasilakis; Christos S Mantzoros
Journal:  Metabolism       Date:  2018-05-09       Impact factor: 8.694

7.  Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density.

Authors:  Rosa Anna DeFilippis; Colleen Fordyce; Kelley Patten; Hang Chang; Jianxin Zhao; Gerald V Fontenay; Karla Kerlikowske; Bahram Parvin; Thea D Tlsty
Journal:  Cancer Res       Date:  2014-08-29       Impact factor: 12.701

8.  Activin-A in myometrium: characterization of the actions on myometrial cells.

Authors:  Pasquapina Ciarmela; Ezra Wiater; Wylie Vale
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

9.  Serum inhibin B correlates with successful ovulation in infertile women.

Authors:  S Luisi; M Palumbo; G Calonaci; V De Leo; S Razzi; P Inaudi; G Cobellis; F Petraglia
Journal:  J Assist Reprod Genet       Date:  2003-06       Impact factor: 3.412

10.  Changes in the reproductive function and developmental phenotypes in mice following intramuscular injection of an activin betaA-expressing plasmid.

Authors:  Mi-Nyeu Kim; Moon Nyeo Park; Hoi Kyung Jung; Chunghee Cho; Kelly E Mayo; Byung-Nam Cho
Journal:  Reprod Biol Endocrinol       Date:  2008-12-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.